FAP and neoplasm: However, a prolonged circulation time of FAP-targeting antibodies and limited tumor retention were reported, since the radioligand binds to fibroblasts in the tumor microenvironment rather than to tumor cells themselves, in contrast to radioligand therapy with prostate-specific membrane antigens.